Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer. Herzog SK, Stevens JH, Gu G, Grimm SL, et al. Cancer Res 2026 Jan 7. doi: 10.1158/0008-5472.CAN-24-3891.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Herzog SK, Stevens JH, Gu G, Grimm SL, et al. Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer. Cancer Res 2026 Jan 7. doi: 10.1158/0008-5472.CAN-24-3891.
PMID: 41499130